Ivosidenib
18-123
Phase 1 small_molecule completed
Quick answer
Ivosidenib for IDH1 Mutation Myeloid Neoplasms is a Phase 1 program (small_molecule) at Agios Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Agios Netherlands B.V.
- Indication
- IDH1 Mutation Myeloid Neoplasms
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed